Free Trial

Regeneron Pharmaceuticals (REGN) Stock Price, News & Analysis

+18.02 (+1.74%)
(As of 07/8/2024 ET)
Today's Range
50-Day Range
52-Week Range
366,178 shs
Average Volume
436,890 shs
Market Capitalization
$115.95 billion
P/E Ratio
Dividend Yield
Price Target

Regeneron Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.77 Rating Score
2.3% Downside
$1,027.55 Price Target
Short Interest
1.68% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.53mentions of Regeneron Pharmaceuticals in the last 14 days
Based on 23 Articles This Week
Insider Trading
Selling Shares
$62.51 M Sold Last Quarter
Proj. Earnings Growth
From $37.23 to $40.47 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.90 out of 5 stars

Medical Sector

185th out of 876 stocks

Pharmaceutical Preparations Industry

74th out of 416 stocks

REGN stock logo

About Regeneron Pharmaceuticals Stock (NASDAQ:REGN)

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

REGN Stock Price History

REGN Stock News Headlines

Bitcoin’s Biggest Year Yet
2024 is set to be a historic year for Bitcoin. It’s all thanks to three major catalysts that I reveal in my newest video.
3 No-Brainer Stocks to Buy in July
3 Pharma Stocks Already Ushering in the Next Biotech Boom
Bitcoin’s Biggest Year Yet
2024 is set to be a historic year for Bitcoin. It’s all thanks to three major catalysts that I reveal in my newest video.
See More Headlines
Receive REGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Confirmed)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
22 Analysts


Net Income
$3.95 billion
Pretax Margin


Sales & Book Value

Annual Sales
$13.12 billion
Cash Flow
$44.03 per share
Book Value
$236.63 per share


Free Float
Market Cap
$115.95 billion

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Should I Buy Regeneron Pharmaceuticals Stock? REGN Pros and Cons Explained


Here are some ways that investors could benefit from investing in Regeneron Pharmaceuticals, Inc.:

  • Regeneron Pharmaceuticals has a strong track record of developing innovative medicines for various diseases, showcasing a commitment to research and development.
  • The company's stock price has shown consistent growth, reaching a 12-month high of $1,042.66, indicating positive investor sentiment.
  • Regeneron Pharmaceuticals reported a net margin of 29.45% and a return on equity of 16.83%, demonstrating strong financial performance.
  • Analysts have issued mostly positive ratings for the company, with an average rating of "Moderate Buy" and an average price target of $991.18, suggesting potential for stock price appreciation.
  • Institutional investors and hedge funds have been increasing their stakes in Regeneron Pharmaceuticals, indicating confidence in the company's future growth prospects.


Investors should be bearish about investing in Regeneron Pharmaceuticals, Inc. for these reasons:

  • One research analyst has issued a sell rating for the stock, indicating some concerns about the company's performance or future outlook.
  • Regeneron Pharmaceuticals missed analysts' consensus estimates for earnings per share in the latest quarter, which could raise doubts about its ability to meet financial expectations.
  • The company's price-to-earnings ratio of 30.62 and PEG ratio of 2.14 may suggest that the stock is currently overvalued compared to its earnings growth potential.
  • While the stock has shown growth, the current market conditions or industry challenges could impact future performance and stock price stability.
  • Investors should consider the company's debt-to-equity ratio of 0.10 and other financial ratios to assess the level of financial risk associated with investing in Regeneron Pharmaceuticals.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, July 2, 2024. Please send any questions or comments about these Regeneron Pharmaceuticals pros and cons to

REGN Stock Analysis - Frequently Asked Questions

How have REGN shares performed this year?

Regeneron Pharmaceuticals' stock was trading at $878.29 at the start of the year. Since then, REGN stock has increased by 19.8% and is now trading at $1,052.25.
View the best growth stocks for 2024 here

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) issued its quarterly earnings data on Thursday, May, 2nd. The biopharmaceutical company reported $7.97 earnings per share for the quarter, missing analysts' consensus estimates of $8.46 by $0.49. The biopharmaceutical company had revenue of $3.15 billion for the quarter, compared to the consensus estimate of $3.19 billion. Regeneron Pharmaceuticals had a net margin of 29.45% and a trailing twelve-month return on equity of 16.83%.

What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO?

423 employees have rated Regeneron Pharmaceuticals Chief Executive Officer Leonard S. Schleifer on Leonard S. Schleifer has an approval rating of 87% among the company's employees.

Does Regeneron Pharmaceuticals have any subsidiaries?

Regeneron Pharmaceuticals subsidiaries include Eastside Campus Holdings LLC, Loop Road Holdings LLC, Old Saw Mill Holdings LLC, OSMR Holdings, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, and more.

Who are Regeneron Pharmaceuticals' major shareholders?

Top institutional investors of Regeneron Pharmaceuticals include DNB Asset Management AS (0.03%), Boston Common Asset Management LLC (0.03%), Massmutual Trust Co. FSB ADV and Woodstock Corp. Insiders that own company stock include George Yancopoulos, Leonard S Schleifer, Neil Stahl, Andrew J Murphy, Joseph J Larosa, Robert E Landry, Plew Daniel P Van, Arthur F Ryan, Christopher R Fenimore, Marion Mccourt, Joseph L Goldstein, Marc Tessier-Lavigne, Christine A Poon, Michael S Brown, Bonnie L Bassler, Huda Y Zoghbi, N Anthony Coles, P Roy Vagelos and George L Sing.
View institutional ownership trends

How do I buy shares of Regeneron Pharmaceuticals?

Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Regeneron Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ) and Walt Disney (DIS).

This page (NASDAQ:REGN) was last updated on 7/9/2024 by Staff

From Our Partners